Compare AbbVie Inc (ABBV) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Expeditors International of Wshngtn Inc — how do they compare? AbbVie Inc trades at $253.89 (market cap $449.91B), while Expeditors International of Wshngtn Inc trades at $163.61 (market cap $21.68B). The key difference: AbbVie Inc is far larger — about 20.8× Expeditors International of Wshngtn Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | EXPD | |
|---|---|---|
Market Cap | $449.91B | $21.68B |
Sector | Health | Industrials |
52-Week High | $261.07 | $167.57 |
52-Week Low | $184.85 | $111.37 |
Enterprise Value | $513.38B | $20.93B |
Dividend Yield | 2.72% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
EXPD trades at $165.74, down 1.09% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company shows consistent earnings beats, with Q1 2026 EPS of $1.71 surpassing expectations of $1.33. Revenue growth is steady, reaching $11.07B in 2025, while maintaining robust profitability with a net margin of 7.48% and ROE of 36.59%. Recent news highlights EXPD's resilience in transportation services amid industry challenges.
The stock presents a mixed outlook: strong fundamentals and technical momentum support upside potential, but valuation multiples like P/E of 26.77 suggest premium pricing. Risks include economic sensitivity and competitive pressures. Analyst consensus is cautious with 60.61% hold ratings, though price targets indicate limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
